{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:32:33Z","timestamp":1793914353936,"version":"4.8.0"},"reference-count":130,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"World Association for Infectious Diseases and Immunological Disorders","award":["WAidid-2022-01"],"award-info":[{"award-number":["WAidid-2022-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Staphylococcus aureus is an extremely virulent pathogen that is capable of quickly evolving and developing antibiotic resistance. To overcome this problem, new antibiotics have been developed. Some of these have been licenced for use in clinical practice, mainly for the treatment of adults with acute skin and soft tissue infections, in addition to both community-acquired pneumonia (CAP) and nosocomial pneumonia (hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia). In this paper, the main characteristics and clinical use of new licenced anti-staphylococcal drugs have been discussed. In vitro studies have demonstrated that some new anti-staphylococcal antibiotics have better antimicrobial activity and, at least in certain cases, more favourable pharmacokinetic properties and higher safety and tolerability than the presently available anti-staphylococcal drugs. This suggests that they may have a potential use in reducing the risk of failure of S. aureus therapy. However, an in-depth analysis of microbiological and clinical studies carried out with these new drugs seems to indicate that further studies need to be conducted before the problem of resistance of S. aureus to the antibiotics available today can be completely solved. Considering the overall available research, the drugs that are active against S. aureus appear to present a great therapeutic opportunity for overcoming resistance to traditional therapy. There are advantages in the pharmacokinetic characteristics of some of these drugs and they have the potential to reduce hospital stays and economic costs associated with their use.<\/jats:p>","DOI":"10.3390\/antibiotics12040742","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T02:29:15Z","timestamp":1681352955000},"page":"742","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["New Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA)"],"prefix":"10.3390","volume":"12","author":[{"given":"Susanna","family":"Esposito","sequence":"first","affiliation":[{"name":"Pediatric Clinic, Pietro Barilla Children\u2019s Hospital, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-9970","authenticated-orcid":false,"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"},{"name":"Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico Milano, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Curtis","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, The University of Melbourne, Parkville, VIC 3010, Australia"},{"name":"Department of Infectious Diseases, The Royal Children\u2019s Hospital Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3093-363X","authenticated-orcid":false,"given":"Tiziana","family":"Lazzarotto","sequence":"additional","affiliation":[{"name":"Division of Microbiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-9995","authenticated-orcid":false,"given":"Marianna","family":"Meschiari","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Peghin","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Department of Medicine and Surgery, University of Insubria-ASST-Sette Laghi, 21110 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-2585","authenticated-orcid":false,"given":"Carlos","family":"Rodrigo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, 08916 Barcelona, Spain"},{"name":"Germans Trias i Pujol Research Institute, Carretera de Can Ruti, Cam\u00ed de les Escoles, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, 16132 Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-5568","authenticated-orcid":false,"given":"Nicola","family":"Principi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Pietro Barilla Children\u2019s Hospital, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2217\/fmb.09.79","article-title":"Staphylococcus aureus nasal carriage and its contributing factors","volume":"4","author":"Sivaraman","year":"2009","journal-title":"Future Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Esposito, S., Terranova, L., Zampiero, A., Ierardi, V., Rios, W.P., Pelucchi, C., and Principi, N. (2014). Oropharyngeal and nasal Staphylococcus aureus carriage by healthy children. BMC Infect. Dis., 14.","DOI":"10.1186\/s12879-014-0723-9"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1128\/CDLI.8.6.1064-1069.2001","article-title":"Determinants of Staphylococcus aureus nasal carriage","volume":"8","author":"Cole","year":"2001","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1128\/IAI.72.11.6685-6688.2004","article-title":"Human factor in Staphylococcus aureus nasal carriage","volume":"72","author":"Nouwen","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Adams, C.E., and Dancer, S.J. (2020). Dynamic Transmission of Staphylococcus Aureus in the Intensive Care Unit. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17062109"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3181\/00379727-51-13986","article-title":"Resistances of Staphylococcus aureus to the action of penicillin","volume":"51","author":"Rammelkamp","year":"1942","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM195511242532105","article-title":"Emergence of antibiotic-resistant bacteria","volume":"253","author":"Finland","year":"1955","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(48)92166-7","article-title":"Infection by penicillin-resistant staphylococci","volume":"2","author":"Barber","year":"1948","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJM196909182811201","article-title":"Changing staphylococci and staphylococcal infections. A ten-year study of bacteria and cases of bacteremia","volume":"281","author":"Jessen","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1056\/NEJM198905043201806","article-title":"Methicillin-resistant Staphylococcus aureus","volume":"320","author":"Brumfitt","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1073\/pnas.122108599","article-title":"The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA)","volume":"99","author":"Enright","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: An overview of basic and clinical research","volume":"17","author":"Turner","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1469-0691.2006.01573.x","article-title":"The molecular evolution of methicillin-resistant Staphylococcus aureus","volume":"13","author":"Deurenburg","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1128\/AAC.46.3.880-882.2002","article-title":"High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: Results from SENTRY antimicrobial surveillance program, 1998\u20131999","volume":"46","author":"Bell","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1086\/320184","article-title":"Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997\u20131999","volume":"32","author":"Diekema","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1469-0691.2006.01344.x","article-title":"The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus","volume":"12","author":"Appelbaum","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_18","first-page":"269","article-title":"Vancomycin Resistance in Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cabral, S.M., Harris, A.D., Cosgrove, S.E., Magder, L.S., Tamma, P.D., and Goodman, K.E. (2023). Adherence to Antimicrobial Prophylaxis Guidelines for Elective Surgeries across 825 United States Hospitals, 2019\u20132020. Clin. Infect. Dis., Online ahead of print.","DOI":"10.1093\/cid\/ciad077"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dks354","article-title":"The emerging problem of linezolid-resistant Staphylococcus","volume":"68","author":"Gu","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13756-020-00714-9","article-title":"The global prevalence of Daptomycin, Tigecycline, Quinupristin\/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: A systematic review and meta-analysis","volume":"9","author":"Shariati","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106611","DOI":"10.1016\/j.ijantimicag.2022.106611","article-title":"Diagnosis and management of infections caused by multidrug-resistant bacteria: Guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)","volume":"60","author":"Tiseo","year":"2022","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Koulenti, D., Xu, E., Mok, I.Y.S., Song, A., Karageorgopoulos, D.E., Armaganidis, A., Lipman, J., and Tsiodras, S. (2019). Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 7.","DOI":"10.3390\/microorganisms7080270"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/cid\/ciac893","article-title":"Black and White Patients With Staphylococcus aureus Bacteremia Have Similar Outcomes but Different Risk Factors","volume":"76","author":"Ruffin","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.amjmed.2022.10.010","article-title":"Staphylococcus aureus Bacteremia: Towards Oral Step-Down Therapy in Selected Cases","volume":"36","author":"Martellosio","year":"2023","journal-title":"Am. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/IDR.S134497","article-title":"Cefazolin potency against methicillin-resistant Staphylococcus aureus: A microbiologic assessment in support of a novel drug delivery system for skin and skin structure infections","volume":"10","author":"Nicolau","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1128\/AAC.02465-14","article-title":"Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01566-18","article-title":"Ceftobiprole activity against Gram-positive and -negative pathogens collected from the United States in 2006 and 2016","volume":"63","author":"Pfaller","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2147\/IDR.S176369","article-title":"Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014\u20132015","volume":"11","author":"Smart","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.diagmicrobio.2010.10.032","article-title":"In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: Results of the CANWARD 2007\u20132009 study","volume":"69","author":"Walkty","year":"2011","journal-title":"Diagn. Microbiol. Infect Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003088-200847010-00003","article-title":"Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity","volume":"47","author":"Murthy","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"ref_32","unstructured":"Food and Drug Administration (2023, February 15). FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections, Available online: https:\/\/johnsonandjohnson.gcs-web.com\/news-releases\/news-release-details\/fda-issues-complete-response-letter-ceftobiprole-treatment\/."},{"key":"ref_33","unstructured":"European Medicines Agency (2023, February 15). Zeftera. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zeftera-previously-zevtera."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril to vancomycin plus ceftazidime in the treatment of patients with complicated skin and skin structure infection","volume":"46","author":"Noel","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","unstructured":"European Medicines Agency (2021, September 06). Zinforo. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zinforo."},{"key":"ref_39","unstructured":"Allergan (2021, September 06). TEFLARO. Available online: https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/Teflaro-USPI-09_2019-2."},{"key":"ref_40","first-page":"201","article-title":"Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection","volume":"9","author":"Parish","year":"2008","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00149-08","article-title":"In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States","volume":"52","author":"Ge","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijantimicag.2008.12.005","article-title":"Activityof the newcephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia","volume":"33","author":"Morrissey","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: The first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jac\/dkq255","article-title":"CANVAS 2: The second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: Randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bjid.2013.11.005","article-title":"Ceftaroline activity tested against contemporary Latin American bacterial pathogens","volume":"18","author":"Flamm","year":"2014","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1128\/AAC.01867-15","article-title":"In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program","volume":"60","author":"Biedenbach","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkq252","article-title":"Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: Results from an international surveillance study","volume":"65","author":"Jones","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Esposito, S., Carrothers, T.J., Riccobene, T., Stone, G.G., and Kantecki, M. (2021). Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia. Paediatr. Drugs, ahead of print.","DOI":"10.1007\/s40272-021-00468-w"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ja.2014.111","article-title":"Glycopeptide antibiotics: Back to the future","volume":"67","author":"Butler","year":"2014","journal-title":"J. Antibiot."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","unstructured":"VANCOCIN\u00ae (Vancomycin Hydrochloride) (2021, September 06). Prescribing Information. ANI Pharmaceuticals, Inc, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/060180s047lbl.pdf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","article-title":"Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children","volume":"158","author":"McKamy","year":"2011","journal-title":"J. Pediatr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review","volume":"75","year":"2015","journal-title":"Drugs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.7164\/antibiotics.47.1493","article-title":"Amides of deacetylglucosaminyl-deoxy teicoplanin active against highly glycopeptide-resistant enterococci. Synthesis and antibacterial activity","volume":"47","author":"Malabarba","year":"1994","journal-title":"J. Antibiot."},{"key":"ref_59","unstructured":"Food and Drug Administration (2021, September 06). FDA Approved Drugs. Dalvabancin Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021883s000lbl.pdf."},{"key":"ref_60","unstructured":"(2021, September 06). European Medicines Agency Xydalba, INN-dalbavancin Hydrochloride. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xydalba-epar-product-information_en.pdf."},{"key":"ref_61","unstructured":"Food and Drug Administration (2021, September 06). Vibativ, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/022110s012lbl.pdf."},{"key":"ref_62","unstructured":"European Medicines Agency (2021, September 06). Vibativ. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/vibativ-epar-summary-public_en.pdf."},{"key":"ref_63","unstructured":"Food and Drug Administration (2021, September 06). FDA Approved Drugs. Label. Dalbavancin, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021883s010lbl.pdf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00228-015-1847-6","article-title":"Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment","volume":"71","author":"Worboys","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40261-015-0340-4","article-title":"Pharmacokinetics, safety, and tolerability of a single 500-mg or 1000-mg intravenous dose of dalbavancin in healthy Japanese subjects","volume":"35","author":"Scoble","year":"2015","journal-title":"Clin. Drug. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/AAC.49.1.148-152.2005","article-title":"Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose","volume":"49","author":"Fetterly","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","first-page":"39","article-title":"Oritavancin for the treatment of acute bacterial skin and skin structure infections: An evidence-based review","volume":"10","author":"Kmeid","year":"2015","journal-title":"Core Evid."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-015-0430-x","article-title":"Dalbavancin: A review in acute bacterial skin and skin structure infections","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"ref_69","first-page":"1477","article-title":"Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: A systematic review and meta-analysis","volume":"21","author":"Nava","year":"2020","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jgar.2020.11.018","article-title":"Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections","volume":"24","author":"Wang","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/INF.0000000000001538","article-title":"Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age","volume":"36","author":"Gonzalez","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/INF.0000000000000646","article-title":"Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age","volume":"34","author":"Bradley","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_73","unstructured":"ABBVIE (2021, September 06). News Center. DALVANCE\u00ae (Dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients. Available online: https:\/\/news.abbvie.com\/news\/press-releases\/dalvance-dalbavancin-receives-fda-approval-to-treat-acute-bacterial-skin-and-skin-structure-infections-in-pediatric-patients.htm."},{"key":"ref_74","unstructured":"Food and Drug Administration (2021, September 06). Orbactiv, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/206334s003lbl.pdf."},{"key":"ref_75","unstructured":"European Medicines Agency (2021, September 06). Orbactiv. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orbactiv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijantimicag.2016.07.019","article-title":"Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus","volume":"48","author":"Corey","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/phar.2389","article-title":"Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review","volume":"40","author":"Krsak","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/cid\/civ528","article-title":"Skin and soft-tissue infections: A critical review and the role of telavancin in their treatment","volume":"61","author":"Cardona","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/AAC.02330-13","article-title":"Telavancin for hospital-acquired pneumonia: Clinical response and 28-day survival","volume":"58","author":"Corey","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkt490","article-title":"Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure","volume":"69","author":"Torres","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","article-title":"Oxazolidinone antibiotics","volume":"358","author":"Diekema","year":"2001","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"127660","DOI":"10.1016\/j.bmcl.2020.127660","article-title":"Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety","volume":"32","author":"Jiang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"BSR20171125","DOI":"10.1042\/BSR20171125","article-title":"Efficacy and safety of linezolid compared with other treatments for skin and soft tissue infections: A meta-analysis","volume":"38","author":"Li","year":"2018","journal-title":"Biosci Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: A review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug. Des. Devel. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: A systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_87","first-page":"9274","article-title":"Research progress on the oxazolidinone drug linezolid resistance","volume":"24","author":"Liu","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1097\/01.inf.0000086954.43010.63","article-title":"Linezolid pharmacokinetics in pediatric patients: An overview","volume":"22","author":"Jungbluth","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.inf.0000078160.29072.42","article-title":"Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1749-6632.2011.05962.x","article-title":"Linezolid, the first oxazolidinone antibacterial agent","volume":"1222","author":"Leach","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_91","unstructured":"ZYVOX\u00ae (Linezolid) (2020, May 20). Prescribing Information. Pfizer Inc. Available online: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?format=PDF&id=649."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/bdd.255","article-title":"Linezolid absolute bioavailability and the effect of food on oral bioavailability","volume":"22","author":"Welshman","year":"2001","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1086\/338403","article-title":"Thrombocytopenia associated with linezolid therapy","volume":"34","author":"Attassi","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1093\/jac\/dkr285","article-title":"Use of linezolid in infants and children: A retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases","volume":"66","author":"Garazzino","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jac\/dkr522","article-title":"A comparative evaluation of adverse platelet outcomes among Veterans\u2019 Affairs patients receiving linezolid or vancomycin","volume":"67","author":"Patel","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4088\/PCC.09r00853","article-title":"Linezolid and serotonin syndrome","volume":"11","author":"Quinn","year":"2009","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_99","unstructured":"US Food and Drug Administration (2021, September 06). Drug Trials Snapshot: Sivextro (Tedizolid), Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshot-sivextro-tedizolid."},{"key":"ref_100","unstructured":"European Medicines Agency (2021, September 06). Sivextro. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sivextro#authorisation-details-section."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1089\/mdr.2018.0457","article-title":"Antibacterial Activity of Tedizolid, a Novel Oxazolidinone Against Methicillin-Resistant Staphylococcus aureus: A Systematic Review and Meta-Analysis","volume":"25","author":"Mojtahedi","year":"2019","journal-title":"Microb. Drug Resist."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e02252-18","DOI":"10.1128\/AAC.02252-18","article-title":"Efficacy and safety of tedizolid phosphate versus linezolid in a randomized phase 3 trial in patients with acute bacterial skin and skin structure infection","volume":"63","author":"Lv","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","article-title":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan\u2014Results of a randomised, multicentre phase 3 study","volume":"24","author":"Mikamo","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs. linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/INF.0000000000003030","article-title":"Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age","volume":"40","author":"Arrieta","year":"2021","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1128\/AAC.00431-13","article-title":"In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions","volume":"57","author":"Flanagan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Lan, S.H., Lin, W.T., Chang, S.P., Lu, L.C., Chao, C.M., Lai, C.C., and Wang, J.H. (2019). Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis. Antibiotics, 8.","DOI":"10.3390\/antibiotics8030137"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1749-6632.2011.06354.x","article-title":"The history of the tetracyclines","volume":"1241","author":"Nelson","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1086\/505494","article-title":"Tigecycline: A critical analysis","volume":"43","author":"Stein","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","article-title":"Omadacycline: Development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections","volume":"11","author":"Villano","year":"2016","journal-title":"Future Microbiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1128\/AAC.01393-16","article-title":"Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects","volume":"60","author":"Sun","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","unstructured":"U.S. Food and Drug Administration (2021, September 06). Drug Approval Package: NUZYRA, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/209816Orig1s000,209817Orig1s000TOC.cfm."},{"key":"ref_114","unstructured":"European Medicines Agency (2021, September 06). Nuzyra: Withdrawal of the Marketing Authorisation Application. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/nuzyra."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for Acute Bacterial Skin and Skin-Structure Infections","volume":"380","author":"Green","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_116","unstructured":"O\u2019Riordan, W., Cardenas, C., Sirbu, A., Garrity-Ryan, L., Das, A.F., Eckburg, P.B., Manley, A., Steenbergen, J.N., Tzanis, E., and McGovern, P. (2018, January 21\u201324). A phase 3 randomized, double-blind, multi-centre study to compare the safety and efficacy of oral omadacycline to oral linezolid for treating adult subjects with ABSSSI (OASIS-2 study). Proceedings of the 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for Community-Acquired Bacterial Pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/cid\/ciz398","article-title":"An integrated safety summary of the novel aminomethylcycline antibiotic omadacycline","volume":"69","author":"Opal","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/000992280204100402","article-title":"Tetracyclines in pediatrics revisited","volume":"41","author":"Shetty","year":"2002","journal-title":"Clin. Pediatr."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/0974-2727.119862","article-title":"Fluoroquinolone Therapy in Staphylococcus aureus Infections: Where Do We Stand?","volume":"5","author":"Gade","year":"2013","journal-title":"J. Lab. Physicians"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e02609","DOI":"10.1128\/AAC.02609-16","article-title":"In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","unstructured":"U.S. Food and Drug Administration (2021, September 06). Drug Approval Package: Baxdela, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208610s007,208611s006lbl.pdf."},{"key":"ref_123","unstructured":"European Medicines Agency (2021, September 06). Quofenix. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/quofenix#authorisation-details-section."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: A Phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study","volume":"67","author":"McManus","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e01949-19","DOI":"10.1128\/AAC.01949-19","article-title":"Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial","volume":"64","author":"McCurdy","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijantimicag.2015.01.004","article-title":"Appropriate use of fluoroquinolones in children","volume":"45","author":"Principi","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Nicolas, I., Bordeau, V., Bondon, A., Baudy-Floc\u2019h, M., and Felden, B. (2019). Novel antibiotics effective against gram-positive and -negative multi-resistant bacteria with limited resistance. PLoS Biol., 17.","DOI":"10.1371\/journal.pbio.3000337"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fcimb.2020.00107","article-title":"Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus","volume":"10","author":"Guo","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Terreni, M., Taccani, M., and Pregnolato, M. (2021). New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules, 26.","DOI":"10.3390\/molecules26092671"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/4\/742\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:14:58Z","timestamp":1760123698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/4\/742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":130,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["antibiotics12040742"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12040742","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]}}}